Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another ...

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy rating, ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...